Centrilobular nodules in high resolution computed tomography of the lung in IPAH patients — preliminary data concerning clinico-radiological correlates by Szturmowicz, Monika et al.
ORIGINAL RESEARCH
265
Address for correspondence: Monika Szturmowicz, I Department of Lung Diseases, National Institute of Tuberculosis and Lung Diseases, ul. Płocka 26, 01−138 Warszawa, 
e-mail: monika.szturmowicz@gmail.com
DOI: 10.5603/PiAP.2016.0033
Received: 10.06.2016
Copyright © 2016 PTChP
ISSN 0867–7077
Monika Szturmowicz1, Aneta Kacprzak1, Barbara Burakowska2, Agnieszka Skoczylas3, Iwona Bestry2, 
Jan Kuś1, Anna Fijałkowska4, Adam Torbicki5, Marcin Kurzyna5
1Ist Department of Lung Diseases National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
2Department of Radiology National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
3Freelance statistical analytic
4Department of Cardiology National Research Institute for Mother and Child, Warsaw, Poland
5Department of Cardiovascular and Pulmonary Thromboembolic Disease CMKP, European Heath Centre, Otwock, Poland
Centrilobular nodules in high resolution computed tomography  
of the lung in IPAH patients — preliminary data concerning 
clinico-radiological correlates
The authors declare no financial disclosure
Abstract
Introduction: Inhomogeneity of lung attenuation pattern is observed in high resolution chest computed tomography (HRCT) in 
some IPAH patients despite lack of interstitial lung disease. Such radiological changes are described either as ill-defined centrilo-
bular nodules (CN) or as focal ground glass opacities (FGGO). There is no consensus in the literature, whether they indicate the 
distinct type of IPAH, or pulmonary venoocclusive disease (PVOD) with subtle radiological changes. Thus the aim of the present 
pilot study was to assess the frequency and clinical significance of inhomogenic lung attenuation pattern in IPAH.
Material and methods: 52 IPAH patients (38 females, 14 males, mean age 41 years ± 15 years), entered the study. All available 
chest CT scans were reviewed retrospectively by the experienced radiologist, not aware about the clinical data of the patients.
Results: CN were found in 10 patients (19%), FGGO — in 12 patients (23%). No lymphadenopathy or interlobular septal thicke-
ning suggestive of PVOD were found. The significant differences between CN and the remaining patients included: lower mean 
age — 31 and 43.5 years, (p = 0.02), lack of persistent foramen ovale (PFO) — 0% and 43% (p = 0.03), and higher mean right 
atrial pressure (mRAP) — 12.5 mm Hg and 7.94 mm Hg (p = 0.01). No significant survival differences were observed between 
the groups of CN, FGGO and the remaining patients.
Conclusion: Centrilobular nodules in IPAH were combined with lack of PFO, higher mRAP and younger age of patients.
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Introduction
High resolution computed tomography 
(HRCT) of the lung is an important tool applied 
to the differential diagnosis of pulmonary hyper­
tension (PH). The presence of interstitial lung 
disease or emphysema indicates PH in the course 
of lung pathology [1]. Moreover, significant inter­
stitial lung disease in HRCT excludes idiopathic 
pulmonary arterial hypertension (IPAH) [1].
Nevertheless, nonhomogenous lung attenu­
ation is observed in HRCT in some IPAH pa­
tients, despite lack of interstitial lung disease 
[2]. Such pathological changes are described 
either as ill­defined centrilobular nodules or 
as focal ground glass opacities. The presence 
of centrilobular nodules (CN) combined with 
interlobular septal thickening, enlarged medi­
astinal lymph nodes and occasionally with the 
presence of pleural effusion, may be regarded as 
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the radiological signs suggestive of pulmonary 
venoocclusive disease (PVOD) [3−6]. Some au­
thors found centrilobular nodules both in PVOD 
and in pulmonary capillary haemangiomatosis 
(PCH), with a tendency towards larger nodules 
in PCH patients [7].
In about 5−10% of IPAH patients, CN are 
described as the only radiological abnormality. 
There is no consensus in the literature, wheth­
er such radiological abnormality indicates the 
distinct type of IPAH or PVOD with subtle radio­
logical changes [8]. The answer to this question 
is important, as PVOD is combined with worse 
prognosis, targeted PAH therapy may be harmful 
and lung transplantation has to be taken into 
account in the early course of the disease [9−11].
Thus the aim of the present pilot study was 
to assess the frequency and clinical significance 
of nonhomogenous lung attenuation pattern in 
IPAH patients.
Material and methods
52 IPAH patients (38 females, 14 males, mean 
age 41 years ± 15 years), diagnosed between 1998 
and 2006, entered the study. IPAH was recognized 
in the patients with precapillary PH confirmed by 
right heart catheterization, and defined as mean 
pulmonary artery pressure (mPAP) ≥ 25 mm Hg, 
pulmonary artery wedge pressure (PAWP) ≤ 15 
mm Hg, and pulmonary vascular resistance (PVR) 
> 3 WU [12].
Chronic thromboembolic pulmonary hyper­
tension (CTEPH) was excluded based on negative 
results of chest computed tomography with an­
giography and lung scintigraphy [12]. PH due to 
the lung diseases was excluded based on: negative 
anamnesis concerning lung disease, no significant 
emphysema or fibrosis in HRCT and the results 
of spirometry and body plethysmography (FEV1 ≥ 
60% pred., FVC ≥ 70% pred., TLC ≥ 70% pred.) [1].
IPAH was diagnosed after exclusion of all 
known causes of pulmonary arterial hyperten­
sion [12]. 
The standard procedures in IPAH patients 
consisted of the assessment of functional class 
(FC) according to WHO, arterialized blood gas 
analysis, 6-minute walk test (6MWT) performed on 
the flat ground according to ATS guidelines [13]. 
Serum N­terminal portion of brain natriure tic pro­
peptide (NT­proBNP) was measured with Elecsys 
proBNP immunoassay, Roche Diagnostics, Basel, 
Switzerland. The patients received PAH-specific 
drugs according to current treatment guidelines 
and according to drug availability in Poland [14].
Figure 2. Focal ground glass opacities in high resolution computed 
tomography of the lung of 19-years old female patient with idiopathic 
pulmonary arterial hypertension
Figure 1. Centrilobular nodules in high resolution computed tomo-
graphy of the lung of 31-years old female patient with idiopathic 
pulmonary arterial hypertension
Transoesophageal echocardiography was 
applied to diagnose the presence of persistent 
foramen ovale (PFO).
All available chest CT scans were reviewed 
retrospectively by the experienced radiologist, 
not aware about the clinical data of the patients. 
Nonhomogenous lung attenuation pattern was 
defined as:
1. Centrilobular nodules (CN) — ill­defined 
centrilobular ground glass opacities (Fig. 1).
2. Focal ground glass opacities (FGGO) — gauzy 
areas of ground glass attenuation with cen­
tral or irregular localization, larger than CN 
(Fig. 2).
Monika Szturmowicz et al., Centrilobular nodules in IPAH
267
Table 1. Comparison of clinical and laboratory parameters (means ± SD) in IPAH patients with CN, FGGO and NPA
Parameter CN — 10 pts FGGO — 12 pts NPA — 30 pts p
Age, years 32.1 (13.5) 43.5 (16.3) 43.4 (13.98) 0.06
Gender M:F  4:1  5:1  2:1 0.22
Haemoptysis, no (%) 5 (50%) 3 (25%) 4 (13%) 0.07
PFO, no (%) 0 (0%) 5/9 (56%) 10/26 (38%) 0.03
6MWD, meters 411.2 (82.0) 354.8 (122) 366.9 (131.7) 0.55
WHO FC (I+II/III+IV)  6/4 6/6 19/11 0.52
NT-proBNP pg/ml 3436 (2108) 1568 (1261) 2069 (2165) 0.16
PaO2, mm Hg 68.1 (16.1) 63.9 (12.8) 65.4 (14.5) 0.77
PaCO2, mm Hg 30.1 (3.8) 32 (5.2) 31.1 (4.0) 0.68
CN — centrilobular nodules; FGGO — focal ground glass opacities; NPA — no parenchymal abnormalities; M — males; F — females; PFO — persistent foramen 
ovale; 6MWT — six minutes walking test; WHO FC — World Health Organisation functional class; NT-proBNP — N terminal portion of brain natriuretic propeptide; 
PaO2 — partial oxygen pressure; PaCO2 — partial carbon dioxide pressure
The remaining patients were classified as 
the group with no parenchymal abnormalities in 
HRCT (NPA). 
In most patients with CN and FGGO expiratory 
HRCT was performed to exclude the air­trapping.
The survival time was calculated from the 
date of HRCT assessment until death or until 
the end of 8-year observation time (Jan 2016). 
In transplant recipients the survival time was 
calculated from HRCT until the day of lung 
transplantation.
Statistical methods
Statistical analysis was performed in R en­
vironment. Normality of the distribution of the 
selected parameters was assessed with Shapi ro­ 
­Wilk’s test. Homogeneity of variance was as­
sessed with Batlett’s test. ANOVA test or Krus­
kal­Wallis test were used to compare the values 
of continuous parameters in the groups with CN, 
FGGO and NPA. For two groups’ comparisons, 
F test and T­Student test or U Mann­Whitney 
test were used respectively. Pearson’s chi­square 
test or its modifications if appropriate (i.e. Yates 
correction and Fisher exact test) were applied to 
compare the categorical variables. Kaplan­Meier 
survival curves and log­rank test were used for 
the analysis of prognostic significance of CN and 
FGGO. P < 0.05 was regarded as significant.
Results
CN were found in 10 out of 52 IPAH patients 
(19%): in 7 of them at diagnosis (13%), in 3 (6%) 
— in the course of the disease. In all of them 
CN were described in every subsequent HRCT 
examination. 
FGGO were described in 12 patients (23%). 
They were also seen in every subsequent HRCT 
examination, if such was performed. 
No overlapping of CN and FGGO was ob­
served. No lymphadenopathy or septal lines 
suggestive of PVOD were found.
The clinical data of the patients with CN, 
FGGO and NPA were compared (Table 1).
The CN patients were younger than those with 
FGGO and NPA. The females predomination was 
higher in CN and FGGO groups compared to NPA.
Haemoptysis was more frequent in CN pa­
tients compared to NPA group (50% and 13% 
respectively, p = 0.07). In none of CN patients 
PFO was detected, compared to 56% of FGGO 
patients and 38% of NPA patients (p = 0.03).
Haemodynamic evaluation (Table 2) revealed 
the tendency towards higher mean right atrial 
pressure (mRAP), lower mixed venous blood 
oxygen saturation (satO2mv), and lower cardiac 
index (CI) in CN patients compared to the rema­
ining groups.
Subsequently, the values of selected variables 
were compared between CN group and all the 
remaining patients (Table 3).
The significant differences between CN and 
the remaining patients included: lower mean age 
(31 and 43.5 years, respectively), lack of PFO (0% 
and 43% respectively), and higher mRAP (12.5 
mm Hg and 7.94 mm Hg respectively). Haemop­
tysis was found in 50% of CN and 17% of the 
remaining patients (p = 0.06).
Median survival time was 42 (1.5−116) mon­
ths in CN group, 47.5 (3−120) months in FGGO 
group and 70.5 (11−210) months in NPA group, 
the difference was not statistically significant. Ne­
vertheless, only one out of 10 CN patients (10%) 
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Table 2. Comparison of haemodynamic parameters (means ± SD) in IPAH patients with CN, FGGO and NPA
Parameter  CN — 9 pts  FGGO — 11 pts  NPA — 26 pts p
mPAP (mm Hg) 59.9 (15) 53.8 (11) 54.6 (14.5) 0.38
CI (l/min/m2) 2.42 (1.15) 2.54 (0.5) 2.5 (0.54) 0.16
SatO2 mv (%) 51.9 (10.8) 56 (8.01) 57.8 (8.18) 0.099
mRAP, (mm Hg) 12.5 (4.8) 6.9 (3.88) 8.5 (5.97) 0.12
PVRI (WU/m2) 9.31 (4.14) 6.89 (2.17) 6.4 (2.9) 0.2
Responders, no (%) 3/9 (33) 0/11 (0) 8/26 (31) 0.12
mPAP — mean pulmonary artery pressure; CI — cardiac index; SatO2 mv — mixed venous blood oxygen saturation; mRAP — mean right atrial pressure; PVRI — 
pulmonary vascular resistance index
Table 3. Comparison of the selected variables (mean ± SD) between CN group and the remaining patients
Parameter CN — 10 pts FGGO+NPA — 42 pts p
Age (years) 31.1 (13.5) 43.5 (14.5) 0.02
mRAP (mm Hg) 12.5 (4.8) 7.94 (5.3) 0.01
mPAP (mm Hg) 59.9 (15) 54.3 (13.2) 0.27
CI (l/min/m2) 2.42 (1.15) 2.51 (0.52) 0.08
PVRI (WU/m2) 9.31 (4.14) 6.56 (2.63) 0.12
satO2mv (%) 51.9 (10.8) 57.1 (8.03) 0.11
6MWD (m) 411.2 (82) 363.2 (13.9) 0.29
NT-proBNP (pg/ml) 3436 (2108) 1887 (1869) 0.06
pO2 (mm Hg) 68.1 (16.1) 64.9 (13.9) 0.56
pCO2 (mm Hg) 30.5 (3.8) 31.3 (4.33) 0.39
PFO no (%) 0/10 (0) 15/35 (43) 0.03
haemoptysis 5/10 (50) 7/42 (17) 0.06
The abbreviations are explained in Tables 1 and 2
survived over 8 years, compared to 2/12 (17%) of 
FGGO and 12/30 (40%) of NPA group.
The survival curves of the three groups are 
included in Figure 3. No significant differences 
were observed between the groups (p = 0.662). 
Discussion
In the presented group of IPAH patients, the 
retrospective analysis of HRCT scans revealed the 
presence of CN in 13% of the patients at the time of 
Figure 3. Kaplan-Meier survival curves for IPAH patients according to HRCT result
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diagnosis, and in 6% of the patients they appeared 
in the course of the disease. The frequency of CN at 
diagnosis, reported by our group, was similar to that 
noticed by Montani et al. and Nolan et al. [9, 15]. Ra­
jaram et al. analysed chest CT scans of IPAH patients 
from the ASPIRE study, and described various types 
of ground glass opacities (GGO) in 57% of them, 48% 
of GGO were classified as centrilobular nodules [2]. 
The presence of CN in patients with pulmo­
nary arterial hypertension may rise a suspicion 
of PVOD, especially if they are accompanied by 
thickened septal lines and enlarged mediastinal 
lymph nodes. Such constellation of abnormalities 
at CT scan is often seen in PVOD. In PVOD pre­
dominantly small pulmonary veins are affected and 
that may lead to lung congestion. In Rajaram study 
thickened septal lines were present in 40% of the 
patients with ground glass attenuation pattern, and 
mediastinal lymphadenopathy — in 30% [2]. In the 
presented group of patients, CN were not combined 
with any other radiological signs of PVOD.
The appearance of ill-defined CN seen in our 
group of IPAH patients was quite similar to those 
observed in bronchiolar disorders or hypersensi­
tivity pneumonitis [16, 17]. Nevertheless, as de­
scribed in methods, there was no lung disease in 
anamnesis, no other signs of bronchiolitis, such as 
tree­in­bud pattern, no air­trapping on expiratory 
HRCT, no significant reduction of lung volumes in 
body plethysmography and, thus, the bronchiolar 
pathology or interstitial lung disease presenting 
with centrilobular nodules were excluded [18].
In three of our patients, CN were not de­
scribed on initial HRCT but appeared in the 
course of IPAH progression. This observation 
could suggest that CN might be combined with 
progressive enlargement of small size pulmonary 
vessels. Nevertheless, CN were not observed in 
the remaining patients, in whom worsening of PH 
was found. Thus it is not clear whether CN rep­
resent the enlarged pulmonary vessels in IPAH. 
In the study group, CN described in initial HRCT 
scans, were also present in every subsequent ra­
diological examination, indicating the possibility 
of the distinct phenotype of IPAH rather, than the 
consequence of hemodynamic worsening. 
The other explanation of CN in IPAH was 
given by Nolan et al. who attributed them to the 
presence of cholesterol granulomas developing 
as a result of occult pulmonary haemorrhage or 
the excessive surfactant degradation [15]. Occult 
pulmonary haemorrhage as the possible cause 
of centrilobular nodules was also suggested by 
Rabiller et al. [4], who found significantly higher 
percentages of haemosiderin­laden macrophages 
in bronchoalveolar lavage fluid of PVOD patients 
compared to IPAH patients. This hypothesis may 
be also taken into account in the presented group 
of patients as haemoptysis was observed more 
frequently in CN patients compared to NPA group. 
A very interesting finding was the lack of PFO 
in our group of CN patients. According to our best 
knowledge, this is the first report concerning PFO 
status in CN patients. Lack of PFO might be one 
of the reasons of significantly higher mRAP in CN 
patients compared to the rest of the group. More­
over, the other hemodynamic indices indicated 
the tendency for CN patients to be more severely 
compromised compared to other patients. Such re­
lation may also be depicted by the tendency towards 
higher NT­proBNP levels in CN patients compared 
to the remaining population of IPAH patients.
Despite more severe hemodynamic compro­
mise, the CN patients covered longer distance 
in 6MWT comparing to the others. This might 
illustrate the influence of age on 6MWT [19], as 
CN patients were significantly younger than the 
remaining ones. 
Younger age of the patients and females pre­
dominance in our group of CN patients indicated 
that this population differed from classical PVOD 
population described by Montani et al. [9]. That 
classical PVOD population included mostly the 
older patients, with the larger proportion of males 
than in IPAH.
The prognostic significance of the described 
various forms of nonhomogenous lung attenua­
tion, was difficult to assess due to small groups 
of patients analysed in this pilot study. There 
was, however, a tendency towards better survival 
in the patients with homogenous attenuation of 
the lungs in HRCT scans compared to those with 
CN and with FGGO. The percentage of 8­year 
survivors was 40% in NPA, comparing to 10% 
in CN and 17% in FGGO. Thus, the prognostic 
significance of CN and FGGO in IPAH have to be 
confirmed on larger group of patients.
Summary
CN were found either at the time of diagno­
sis or later in the course of the disease in 19% of 
IPAH patients. They were not accompanied by any 
other radiological features suggestive of PVOD. 
The CN patients were significantly younger, 
with more frequent haemoptysis, lack of PFO 
and higher mRAP, compared to the remaining 
IPAH patients. The prognostic significance of CN 
in IPAH needs further investigations on larger 
groups of patients.
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